Abstract: FR-PO913
Immunosuppressive Therapy (IST)-Related Adverse Events in Patients with Glomerular Disorders (GDs)
Session Information
- Glomerular Diseases: Potpourri
October 25, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Lim, Andrea, Kaiser Permanente San Francisco Medical Center, San Francisco, California, United States
- Roybal, Belia O., Kaiser Permanente Division of Research, Oakland, California, United States
- Yao, Mimi J., Kaiser Permanente San Francisco Medical Center, San Francisco, California, United States
- Shirazi, Aida, Kaiser Permanente San Francisco Medical Center, San Francisco, California, United States
- Lapasia, Jessica B., Kaiser Permanente San Francisco Medical Center, San Francisco, California, United States
- Poyan-Mehr, Ali, Kaiser Permanente San Francisco Medical Center, San Francisco, California, United States
Background
Treatment-emergent adverse events (TAE) in GD patients include infection (IF) and gastrointestinal bleed (GI). Unfortunately, data about TAE prevalence in GD patients receiving IST is scant, and effectiveness of prophylaxis is unknown.
Methods
In this retrospective study, we identified 806 patients with a biopsy-proven GD diagnosis between 1/1/2010 and 10/31/2022 who were treated with IST. We evaluated TAE prevalence within an 18-month follow-up period from time of treatment initiation. We also evaluated risk-modifying factors with baseline clinical characteristics.
Results
The proportion of those with IF- or GI-TAE was highest in vasculitis-related GD (37.4% and 30.1%, respectively) compared to other GD diagnosis categories. Further, IF and GI-TAEs were more prevalent in patients treated with glucocorticoids than other IST (66.4% and 72.6%, respectively). Significant differences in baseline characteristics exist between those with and without TAEs.
Conclusion
Our preliminary results find that IF- and GI-TAEs appear to be more prevalent in those treated with glucocorticoids and those with vasculitis-related GD. A multi-regression analysis is being conducted to identify factors that can identify those at high risk for TAEs.
Funding
- Clinical Revenue Support